PATENT CLAIM ANALYSIS

Application Number: 16012536
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["514", "364000"]

Abstract:
The invention describes compounds that inhibit both HDAC and GSK3β (i.e., HDAC/GSK3β dual inhibitors). The invention further describes compositions containing these HDAC/GSK3β dual inhibitors, as well as methods and kits using these HDAC/GSK3β dual inhibitors to treat various medical conditions. The invention also provides methods and kits using a HDAC inhibitor and a GSK3β to treat various medical conditions, and compositions containing a HDAC inhibitor and a GSK3β. Medical conditions treatable with various embodiments of the invention include but are not limited to cancers and tumors.

Claim (Index 116):
The method of  claim 108 , wherein the compound has the structure of Formula (III): wherein: X is a linker group; and Y is absent or selected from the group consisting of alkyl, CF 3 , NO 2 , CO 2 H, SO 2 H, cyano, hydroxyl, thiol, alkylthio, alkoxy, acyl, halogen, amino, alkyl amino, and dialkylamino.

Metadata:
- Claim Count in Document: 51.0
- Percentile: 94.0
- Lexical Diversity: 1.93878
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15317559', '14510711', '14088804', '12339492', '15834052']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8092808548046826
- 35 USC 102 Novelty (BERT): 0.5995840738244037
- Combined Prediction Score: 0.7883111767066547
- Mean Citation Score: 302.1332940000001
- Max Citation Score: 580.7595
- Similarity Product: 436.4113121573032

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test